Managed Healthcare Executive1d
Cumberland Pharmaceuticals Reports Promising Results Itetroban for DMD Patients
The company is evaluating whether the drug, which targets cardiac complications, might be used treat patients with other ...
Hosted on MSN6d
Cumberland Pharmaceuticals reports data from trial of ifetroban for DMD
High-dose treatment with the therapy was found to cause a 3.3% overall improvement in left ventricular ejection fraction.
FierceBiotech7d
Cumberland's Duchenne drug improves blood flow from heart in phase 2 trial
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
Nashville Post6d
Cumberland Pharmaceuticals sees nearly 60 million shares trade
Shares of Cumberland Pharmaceuticals continued their eye-opening ascent Wednesday on heavy volume.
Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) released topline results from its Phase 2 FIGHT DMD trial. The study evaluated ...
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare diseases, today announced positive top-line results from ...
Cumberland reports progress in DMD heart disease trial
NASHVILLE, Tenn. - Cumberland Pharmaceuticals Inc. (NASDAQ: NASDAQ:CPIX), a specialty pharmaceutical company with a market ...
Nasdaq8d
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
NASHVILLE, Tenn., Feb. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company with development efforts focused on new products for rare ...